Compugen(US:CGEN)2020-05-08 13:01Pipeline Highlights - Compugen has an innovative immuno-oncology portfolio with first-in-class drugs in Phase 1 clinical trials, including COM701, COM902, and BAY1905254[5] - Encouraging preliminary clinical data for COM701 shows signals of anti-tumor activity and is well-tolerated, with a disease control rate of 69% in monotherapy and 75% in combination dose escalation[5, 45, 47] - Durable responses of over six months were observed in 21% (6/28) of patients treated with COM701[5] - COM902, an anti-TIGIT therapeutic monoclonal antibody, is in Phase 1 study for patients with advanced malignancies, with initial data expected in 2021[6, 66] - BAY 1905254, an ILDR2 inhibitor being developed by Bayer, is in Phase 1 clinical development[6] Strategic Collaborations & Financial Position - Strategic collaborations with leading pharma companies like Bristol-Myers Squibb and Bayer validate Compugen's targets and approach[5, 68] - As of March 31, 2020, Compugen had a cash balance of approximately $121 million and no debt[71] - The company's market capitalization was approximately $1 billion as of May 2020[71] - Expected gross cash expenditures for 2020 are approximately $27 million[71] Platform & Vision - Compugen's computational platform is a proven engine for novel drug targets, enabling the identification of new I/O pathways and translation to clinical validation[5, 13] - The company's vision is to transform patient lives by developing first-in-class therapeutics based on its computational target discovery platform[4] - Compugen is addressing a significant unmet need, as 70-80% of patients are non-responsive to approved cancer immunotherapies[14]